IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Acquired by Carolinas Wealth Consulting LLC

Carolinas Wealth Consulting LLC increased its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 43.0% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 123 shares of the company’s stock after acquiring an additional 37 shares during the period. Carolinas Wealth Consulting LLC’s holdings in IDEXX Laboratories were worth $60,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. Riverview Trust Co purchased a new position in shares of IDEXX Laboratories in the first quarter valued at approximately $26,000. Crewe Advisors LLC purchased a new position in IDEXX Laboratories in the 1st quarter valued at approximately $26,000. Ridgewood Investments LLC acquired a new position in shares of IDEXX Laboratories in the second quarter worth $27,000. Institutional & Family Asset Management LLC purchased a new stake in shares of IDEXX Laboratories during the second quarter worth $28,000. Finally, DSM Capital Partners LLC acquired a new stake in shares of IDEXX Laboratories in the fourth quarter valued at $33,000. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

IDXX has been the topic of several recent research reports. StockNews.com downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, July 10th. Piper Sandler reduced their target price on shares of IDEXX Laboratories from $600.00 to $520.00 and set a “neutral” rating on the stock in a report on Wednesday, August 14th. BTIG Research began coverage on shares of IDEXX Laboratories in a research note on Thursday, July 25th. They issued a “buy” rating and a $580.00 price target for the company. Finally, Stifel Nicolaus dropped their price objective on shares of IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating on the stock in a research report on Monday, June 24th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $582.25.

IDEXX Laboratories Stock Up 1.1 %

Shares of NASDAQ:IDXX opened at $517.06 on Friday. The company has a current ratio of 1.37, a quick ratio of 1.03 and a debt-to-equity ratio of 0.33. The firm has a 50 day simple moving average of $483.57 and a 200-day simple moving average of $500.01. The company has a market capitalization of $42.70 billion, a PE ratio of 50.05, a P/E/G ratio of 4.17 and a beta of 1.33. IDEXX Laboratories, Inc. has a twelve month low of $372.50 and a twelve month high of $583.39.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $2.44 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.88 by ($0.44). The business had revenue of $1 billion for the quarter, compared to analysts’ expectations of $1.01 billion. IDEXX Laboratories had a return on equity of 57.03% and a net margin of 22.34%. The company’s revenue for the quarter was up 6.4% on a year-over-year basis. During the same period in the previous year, the business posted $2.67 earnings per share. On average, equities analysts predict that IDEXX Laboratories, Inc. will post 10.45 EPS for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.